Exhibitor & Sponsor Information
The Anxiety and Depression Association sponsors the only annual conference focused exclusively on advancing science and treatment of anxiety, depression and co-occurring disorders. Our mission is twofold: We educate more than 11 million individuals and their families every year about these disorders and help them find treatment, resources, and support. We engage a diverse network of basic and clinical anxiety and depression researchers by promoting scientific innovation while supporting the implementation of evidence-based treatments and best practices to clinicians.
Why Become an ADAA Sponsor?
Collaborating with ADAA provides an opportunity to reach ADAA’s vast network of psychiatrists, social workers, psychologists, counselors and therapists before, during and after the conference. Invest in your customer relationships and make an impact.
ADAA 2022 Sponsorship Packages Coming Soon
For information on sponsorship opportunities, pricing and/or to design a tailored a la carte package to meet your specific goals, please contact Susan Gurley: [email protected] or 240-485-1021.
Rogers Behavioral Health is a leading provider of evidence-based mental health services nationwide. Rogers provides inpatient, residential, and outpatient care for adults, children, and teens with depression and mood disorders, eating disorders, addiction, OCD and anxiety disorders, PTSD, and mental health disorders in kids with autism. Learn more at rogersbh.org.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at @JanssenUS. Janssen Neuroscience is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
VistaGen Therapeutics is developing new generation medications for multiple mental health and neurology markets where current treatments are inadequate to meet the growing needs of millions of patients worldwide. Looking beyond the limitations of current treatments for anxiety, depression and suicidal ideation, VistaGen's pipeline includes three differentiated, late-stage new drug candidates, AV-101, PH10 and PH94B, each with an exceptional safety profile and fast-acting potential to treat these debilitating diseases and disorders. VistaGen is committed to improving mental health by raising awareness of the conditions that affect the daily lives of millions of patients around the world and to introducing novel treatment alternatives into inadequate treatment paradigms. Connect with VistaGen on Twitter, LinkedIn and Facebook.
Established in 1987, the American Foundation for Suicide Prevention is dedicated to saving lives and bringing hope to those affected by suicide. AFSP creates a culture that’s smart about mental health through education and community programs, develops suicide prevention through research and advocacy, and provides support for those affected by suicide.
Anxiety.org provides resources for anxiety help, diagnosis, and treatment, from leading researchers and therapists. Anxiety.org is the online resource trusted by researchers and clinical providers.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome’s core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer’s disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA. For more information, please visit the Company’s website at axsome.com.
Cohen Veterans Network is a 501(c)(3) national nonprofit philanthropic organization for post-9/11 veterans and their families. CVN focuses on improving mental health outcomes, with a goal to build a network of outpatient mental health clinics for veterans and military families in high-need communities, in which trained clinicians deliver holistic evidence-based care to treat mental health conditions. Learn more about CVN.
McLean Hospital offers exceptional care for children and adults who are living with depression and anxiety, including OCD. A top-rated hospital by U.S. News & World Report, compassionate care at McLean is provided using evidence-based treatment methods through short-term inpatient, diagnostically-specific residential, day treatment and intensive outpatient programs.
At Marriott International, our 30 brands are differentiated by design, signature programming and personalized service. From the utmost in Luxury to the efficiency and value of Select Service, we offer every traveler and travel professional the right brand, in the right place, at the right price. With more than 7,000 properties spanning 130 countries and territories, we cover more of the world than any other lodging company. As new destinations emerge, we will be there.
Pathlight Mood & Anxiety Center (Pathlight) is a leading mental health care system dedicated to the treatment of primary mood, anxiety and trauma-related disorders. Working with patients and their families, Pathlight provides innovative and evidence-based treatment programs tailored for patients of all ages, races, ethnicities, religions, sexual identities, gender identities and expressions. For more information, please visit PathlightBH.com.
For over 200 years Wiley has been helping people and organizations develop the skills and knowledge they need to succeed. We develop digital education, learning, assessment, and certification solutions to help universities, businesses, and individuals move between education and employment and achieve their ambitions. By partnering with learned societies, we support researchers to communicate discoveries that make a difference. Our online scientific, technical, medical, and scholarly journals, books, and other digital content build on a 200-year heritage of quality publishing.